Metastatic gastric cancer - focus on targeted therapies

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Gastric cancer (GC) is a leading cause of cancer mortality globally, with many patients diagnosed at advanced or metastatic stages.
• Current treatment modalities including surgery, chemotherapy, and radiotherapy offer limited survival benefits for advanced GC.
• Understanding GC biology is crucial for developing more effective therapeutic strategies.

Purpose of the Study:

• To review current and emerging targeted therapies for gastric cancer.
• To focus on anti-Her-2 therapies and epidermal growth factor receptor antagonists.
• To discuss drugs targeting angiogenesis and other novel agents in development.

Main Methods:

• Review of existing literature on targeted therapies for gastric cancer.
• Focus on drugs targeting specific molecular pathways like Her-2 and angiogenesis.
• Inclusion of agents in preclinical and early clinical development.

Main Results:

• Anti-Her-2 therapy, exemplified by trastuzumab, shows promise.
• Epidermal growth factor receptor antagonists (cetuximab, panitumumab, etc.) are under investigation.
• Angiogenesis inhibitors (bevacizumab, ramucirumab, etc.) and other novel agents (mTOR inhibitors, c-MET inhibitors, etc.) are being explored.

Conclusions:

• Targeted therapies represent a promising frontier for improving gastric cancer treatment.
• Further research and clinical trials are essential to validate the efficacy of these agents.
• Personalized medicine approaches targeting specific molecular pathways hold potential for better patient outcomes in GC.